MedTrace Logo

PULSAR Combined With Immunotherapy and Chemotherapy

NCT07291947 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-12-18

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy and safety of PULSAR in combination with dual immune checkpoint inhibitors (PD-1 monoclonal antibody + CTLA-4 monoclonal antibody) and GC chemotherapy in patients with locally advanced or metastatic cholangiocarcinoma. The secondary objective of this study is to investigate the immunological impact of PULSAR combined with dual immune therapy (PD-1 monoclonal antibody + CTLA-4 monoclonal antibody) on the tumor microenvironment and systemic immune responses in cholangiocarcinoma patients.

Conditions

Interventions

DRUG

Iparomlimab and Tuvonralimab Injection (QL1706)

GC chemotherapy and Iparomlimab and Tuvonralimab Injection

RADIATION

PULSAR

Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy

Sponsors & Collaborators

  • Wang Xin

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-04
Primary Completion
2026-09-10
Completion
2027-09-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07291947 on ClinicalTrials.gov